These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. The rationale for drug combinations in age-related macular degeneration. Adamis AP Retina; 2009 Jun; 29(6 Suppl):S42-4. PubMed ID: 19553800 [TBL] [Abstract][Full Text] [Related]
9. Opportunities and challenges in the development of combination therapy for the treatment of retinal diseases. Hohman TC Retina; 2009 Jun; 29(6 Suppl):S51-3. PubMed ID: 19553804 [TBL] [Abstract][Full Text] [Related]
11. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration. Arias L; Ruiz-Moreno JM; Gómez-Ulla F; Fernández M; Montero J Retina; 2009; 29(10):1444-9. PubMed ID: 19730163 [TBL] [Abstract][Full Text] [Related]
12. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292 [TBL] [Abstract][Full Text] [Related]
13. Overview of radiation trials for age-related macular degeneration. Kaiser PK Retina; 2009 Jun; 29(6 Suppl):S34-5. PubMed ID: 19553797 [TBL] [Abstract][Full Text] [Related]
14. Combination therapy using the small interfering RNA bevasiranib. Singerman L Retina; 2009 Jun; 29(6 Suppl):S49-50. PubMed ID: 19553802 [TBL] [Abstract][Full Text] [Related]